MET overexpression

This real-world study suggests that MET overexpression, as assessed by IHC, is associated with better survival in advanced NSCLC patients treated with ICIs, independent of PD-L1 level. These results suggest the potential of MET expression as a predictive marker for ICI efficacy in advanced NSCLC patients and support the combination of MET-targeted agents with anti-PD1/PD-L1 ICIs as a promising strategy for NSCLC patients with MET overexpression.

We further integrated cancer patient-derived organoid (PDO) data on drug sensitivity into the QSP framework and explored the translational utility of this hybrid drug analysis paradigm towards the design of optimal personalized treatment regimens for 5 NSCLC patients harboring MET amplification. To our knowledge, our work is the first multiscale QSP investigation of MET dysregulation for translational cancer drug research, and by integrating QSP model analyses with PDO data it has opened up a new route to facilitate future cancer personalized medicine.

These cells exhibited markedly enhanced cytotoxicity against tumour cells overexpressing c-Met, accompanied by increased release of key effector cytokines such as interferon-γ. This research framework offers a precise, synergistic therapeutic strategy to overcome limitations in CAR-T therapy response within serous ovarian carcinoma.

It also regulated cell adhesion and migration while reducing global protein synthesis via the downregulation of the PI3K/Akt/mTOR pathway. Our results together identify miR-6850 as a tumor-suppressive miRNA in HGSOC, demonstrating its diverse anti-oncogenic actions and underscoring its potential as a prognostic biomarker and therapeutic target in ovarian cancer.

Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.

These data suggest that c-Met protein OE is associated with MET mRNA expression, shows limited overlap with other MET aberrations, and may be linked to poor prognosis in NSCLC.

Considering pasireotide's potential to target c-MET and EGFR pathways, our findings provide a strong rationale for its further preclinical validation in the treatment of TNBC. The demonstrated efficacy and safety of pasireotide in this aggressive subtype of cancer can now be evaluated through subsequent studies.

Specifically, our study demonstrated: (1) The MET gene is significantly overexpressed in THCA tissues compared to normal controls; (2) This dysregulation is closely associated with aggressive malignant phenotypes, including enhanced tumor progression, increased metastatic potential, reduced survival, and immune-suppressive characteristics; (3) Retrospective clinical case analysis indicated that the lymph node metastasis rate was significantly elevated in the MET high-expression group relative to the low-expression group; (4) RNA interference (RNAi)-mediated MET knockdown resulted in a marked decrease in the migratory and invasive capacities of thyroid cancer cells in vitro. Collectively, these findings not only identify MET as a robust molecular classifier for THCA but, more critically, uncover its therapeutic potential as an actionable target within the HGF/c-MET axis for refractory THCA, providing both experimental evidence and a theoretical framework for developing precision diagnostic and therapeutic strategies.

P2, N=270, Active, not recruiting, AbbVie | Trial primary completion date: Oct 2025 --> Jul 2026

P1, N=30, Terminated, Regeneron Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Oct 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Oct 2025; Sponsor decision

P=N/A, N=9, Not yet recruiting, Beijing Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University

P=N/A, N=64, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University